Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 42.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 641,684 shares of the company’s stock after purchasing an additional 191,345 shares during the quarter. Vontobel Holding Ltd.’s holdings in Sutro Biopharma were worth $2,753,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in shares of Sutro Biopharma by 14,125.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock worth $38,000 after acquiring an additional 8,758 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Sutro Biopharma by 331.7% during the fourth quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after purchasing an additional 4,372 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Sutro Biopharma in the 2nd quarter valued at $46,000. Tower Research Capital LLC TRC increased its stake in Sutro Biopharma by 342.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock worth $52,000 after purchasing an additional 11,708 shares in the last quarter. Finally, Ergoteles LLC acquired a new stake in Sutro Biopharma during the 2nd quarter worth about $54,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Insider Buying and Selling at Sutro Biopharma

In other news, insider Nicki Vasquez sold 12,185 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $5.00, for a total transaction of $60,925.00. Following the completion of the sale, the insider now directly owns 12,803 shares of the company’s stock, valued at approximately $64,015. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

STRO has been the subject of several recent analyst reports. HC Wainwright decreased their target price on shares of Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, March 26th. Truist Financial decreased their price objective on shares of Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. Oppenheimer reissued an “outperform” rating and set a $10.00 target price on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 target price (down previously from $12.00) on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Sutro Biopharma has an average rating of “Buy” and a consensus price target of $12.57.

Sutro Biopharma Stock Performance

Sutro Biopharma stock opened at $3.77 on Friday. Sutro Biopharma, Inc. has a 12 month low of $2.01 and a 12 month high of $6.13. The company’s fifty day simple moving average is $4.49 and its 200-day simple moving average is $3.87.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.